Form 4: AEON Biopharma Executive VP Alexander Blair Wilson Reports Stock and Option Awards
SEC Form 4
Alexander Blair Wilson, Executive VP, CLO & Corporate Secretary of AEON Biopharma, reports the acquisition of restricted stock units and stock options.
Summary
- On August 31, 2024, Alexander Blair Wilson, Executive VP, CLO & Corporate Secretary of AEON Biopharma, was granted 180,110 shares of Class A Common Stock as restricted stock units.
- These restricted stock units vest in full on the second anniversary of the grant date, contingent upon continued service.
- Wilson also received an award of 480,631 stock options on August 31, 2024, which vest in substantially equal monthly installments over the eighteen months following the grant date, also contingent upon continued service.
- The exercise price of these options is $0.83.
- Additionally, the report corrects a previous error, reclassifying 81,428 restricted stock units granted on April 26, 2023, from derivative securities to common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The filing reflects standard executive compensation practices, which are generally viewed favorably as they align executive interests with shareholder value. There are no indications of negative events or concerns.
Positives
- The grant of restricted stock units and stock options to a key executive aligns their interests with the long-term performance of the company.
- The vesting schedules for both the restricted stock units and stock options incentivize continued service.
Industry Context
Form 4 filings are standard practice and provide transparency into the equity holdings and transactions of company insiders, which is crucial for investor confidence and market efficiency.
Comparison to Industry Standards
- Equity compensation is a common practice in the biopharmaceutical industry to attract and retain key talent.
- The vesting schedules and option terms are generally in line with industry standards for executive compensation packages.
- Comparing the size of the grants to similar companies and executive roles would provide further context on the competitiveness of AEON Biopharma's compensation practices.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning executive interests with company performance.
- Employees may see the grants as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/26/2023 | Original grant date of 81,428 restricted stock units (RSUs) that were incorrectly reported as derivative securities. |
| 07/24/2023 | Previous report date where RSUs were incorrectly reported as derivative securities. |
| 08/31/2024 | Date of grant for 180,110 restricted stock units and 480,631 stock options. |
| 08/30/2034 | Expiration date of the stock options granted on August 31, 2024. |
| 09/04/2024 | Date of the Form 4 filing. |
Keywords
stock options, restricted stock units, Form 4, beneficial ownership, AEON Biopharma, Alexander Blair Wilson, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.